900 related articles for article (PubMed ID: 35359967)
1. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2022; 13():840126. PubMed ID: 35359967
[TBL] [Abstract][Full Text] [Related]
2. Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report.
Nyström K; Hjorth M; Fust R; Nilsdotter-Augustinsson Å; Larsson M; Niward K; Nyström S
BMC Infect Dis; 2022 Apr; 22(1):362. PubMed ID: 35410137
[TBL] [Abstract][Full Text] [Related]
3. Reactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology.
Steiner S; Schwarz T; Corman VM; Sotzny F; Bauer S; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2021; 12():687449. PubMed ID: 34322120
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
Lindemann M; Krawczyk A; Dolff S; Konik M; Rohn H; Platte M; Thümmler L; Schwarzkopf S; Schipper L; Bormann M; van de Sand L; Breyer M; Klump H; Knop D; Lenz V; Temme C; Dittmer U; Horn PA; Witzke O
J Med Virol; 2021 May; 93(5):3047-3054. PubMed ID: 33527424
[TBL] [Abstract][Full Text] [Related]
5. Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response.
Herman JD; Wang C; Loos C; Yoon H; Rivera J; Eugenia Dieterle M; Haslwanter D; Jangra RK; Bortz RH; Bar KJ; Julg B; Chandran K; Lauffenburger D; Pirofski LA; Alter G
Nat Commun; 2021 Nov; 12(1):6853. PubMed ID: 34824251
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
[TBL] [Abstract][Full Text] [Related]
7. Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.
Mizera D; Dziedzic R; Drynda A; Gradzikiewicz A; Jakieła B; Celińska-Löwenhoff M; Padjas A; Matyja-Bednarczyk A; Zaręba L; Bazan-Socha S
Front Immunol; 2023; 14():1275892. PubMed ID: 37901210
[TBL] [Abstract][Full Text] [Related]
8. Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency.
Kinoshita H; Durkee-Shock J; Jensen-Wachspress M; Kankate VV; Lang H; Lazarski CA; Keswani A; Webber KC; Montgomery-Recht K; Walkiewicz M; Notarangelo LD; Burbelo PD; Fuss I; Cohen JI; Bollard CM; Keller MD
J Clin Immunol; 2021 Aug; 41(6):1146-1153. PubMed ID: 33983545
[TBL] [Abstract][Full Text] [Related]
9. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
Front Immunol; 2021; 12():684014. PubMed ID: 34194438
[TBL] [Abstract][Full Text] [Related]
10. Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection.
Orologas-Stavrou N; Politou M; Rousakis P; Kostopoulos IV; Ntanasis-Stathopoulos I; Jahaj E; Tsiligkeridou E; Gavriatopoulou M; Kastritis E; Kotanidou A; Dimopoulos MA; Tsitsilonis OE; Terpos E
Viruses; 2020 Dec; 13(1):. PubMed ID: 33375675
[TBL] [Abstract][Full Text] [Related]
11. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency.
Lang-Meli J; Fuchs J; Mathé P; Ho HE; Kern L; Jaki L; Rusignuolo G; Mertins S; Somogyi V; Neumann-Haefelin C; Trinkmann F; Müller M; Thimme R; Umhau M; Quinti I; Wagner D; Panning M; Cunningham-Rundles C; Laubner K; Warnatz K
J Clin Immunol; 2022 Feb; 42(2):253-265. PubMed ID: 34893946
[TBL] [Abstract][Full Text] [Related]
12. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
[TBL] [Abstract][Full Text] [Related]
14. Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.
Tang J; Grubbs G; Lee Y; Golding H; Khurana S
Clin Infect Dis; 2022 Jan; 74(2):327-334. PubMed ID: 33861337
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
16. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
Rnjak D; Ravlić S; Šola AM; Halassy B; Šemnički J; Šuperba M; Hećimović A; Kurolt IC; Kurtović T; Mačak Šafranko Ž; Polančec D; Bendelja K; Mušlin T; Jukić I; Vuk T; Zenić L; Artuković M
Transfus Clin Biol; 2021 Aug; 28(3):264-270. PubMed ID: 33901641
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 convalescent plasma composition and immunological effects in severe patients.
Acosta-Ampudia Y; Monsalve DM; Rojas M; Rodríguez Y; Gallo JE; Salazar-Uribe JC; Santander MJ; Cala MP; Zapata W; Zapata MI; Manrique R; Pardo-Oviedo JM; Camacho B; Ramírez-Santana C; Anaya JM;
J Autoimmun; 2021 Mar; 118():102598. PubMed ID: 33524876
[TBL] [Abstract][Full Text] [Related]
19. The Quality of Anti-SARS-CoV-2 T Cell Responses Predicts the Neutralizing Antibody Titer in Convalescent Plasma Donors.
Kroemer M; Boullerot L; Ramseyer M; Spehner L; Barisien C; Gravelin E; Renaudin A; Cognasse F; Gallian P; Hermine O; Lacombe K; Tiberghien P; Adotévi O
Front Public Health; 2022; 10():816848. PubMed ID: 35372242
[TBL] [Abstract][Full Text] [Related]
20. SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients.
Silva LTD; Ortega MM; Tiyo BT; Viana IFT; Lima TE; Tozetto-Mendoza TR; Oliveira LMDS; Teixeira FME; Lins RD; Almeida A; Mendes-Correa MC; Duarte AJDS; Oshiro TM
Clinics (Sao Paulo); 2021; 76():e3548. PubMed ID: 34878034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
